Our study uncovered that the UBC9 inhibitor 2-D08 possesses high potency to suppress PCa cell proliferation and to promote TAM function, but has no effect on tumor cell–mediated CD8+ T cell activation. This evidence concerns the gene CD8A and neoplasm.